AMN107; 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide
641571-10-0
529.5
C28H22F3N7O
DMF, DMSO
-20°C
A potent, selective BCR-ABL inhibitor that fits into the ATP-binding site of the BCR-ABL protein with higher affinity than imatinib (Cat. No. 1625-100, 1000). Nilotinib is not only more potent than imatinib against wild-type BCR-ABL (IC< 30 nM), but also significantly active against 32/33 imatinib-resistant BCR-ABL mutants.
0.1 lbs
Research or further manufacturing use only, not for food or drug use.
